Alzamend Neuro (Alzamend Neuro) Net Margin % : 0.00% (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Alzamend Neuro's Net Income for the three months ended in Jan. 2024 was $-2.66 Mil. Alzamend Neuro's Revenue for the three months ended in Jan. 2024 was $0.00 Mil. Therefore, Alzamend Neuro's net margin for the quarter that ended in Jan. 2024 was 0.00%.

The historical rank and industry rank for Alzamend Neuro's Net Margin % or its related term are showing as below:

ALZN's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -151.78
* Ranked among companies with meaningful Net Margin % only.

Alzamend Neuro Net Margin % Historical Data

The historical data trend for Alzamend Neuro's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Net Margin % Chart

Alzamend Neuro Annual Data

Trend

Apr19

Apr20

Apr21

Apr22

Apr23

Net Margin %

Alzamend Neuro Quarterly Data
	Apr19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Net Margin %	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Alzamend Neuro's Net Margin %

For the Biotechnology subindustry, Alzamend Neuro's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzamend Neuro's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Net Margin % distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's Net Margin % falls into.

Alzamend Neuro Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Alzamend Neuro's Net Margin for the fiscal year that ended in Apr. 2023 is calculated as

Net Margin	=	Net Income (A: Apr. 2023 )	/	Revenue (A: Apr. 2023 )
	=	-14.878	/	0
	=	%

Alzamend Neuro's Net Margin for the quarter that ended in Jan. 2024 is calculated as

Net Margin	=	Net Income (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-2.662	/	0
	=	%

Alzamend Neuro (NAS:ALZN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Alzamend Neuro Net Margin % Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzamend Neuro (Alzamend Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326

Website

https://www.alzamend.com

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Executives

Ault Milton C Iii	10 percent owner	11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff	officer: Chief Operating Officer	201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman	director, officer: Chief Executive Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath	director	28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson	director	10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne	director	C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser	director, officer: Exec VP and General Counsel	100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun	officer: SVP of Finance	3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram	director	15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien	officer: Chief Financial Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo	director	2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404